-
Annual Report 2022: Time to move to the next stage2023-09-06
-
HA130- Improve the quality of life for dialysis pa...2023-09-06
-
Jafron Recognized as National Enterprise Technolog...2023-09-06
-
HA380 hemoperfusion cartridge-- Essential treatmen...2023-09-06
-
Golden Bull Award! Jafron Wins Golden Bull Award ...2023-09-06
-
Expert Consensus on Artificial Liver Therapy2023-09-06
-
Mr. Jean Paul Menneguerre, Senior Head of the EMEA...2023-09-06
-
Jafron in Jordan: Facilitator of the Local Healthc...2023-09-06
-
ESICM: Getting to Know Jafron from Different Persp...2023-09-06
-
Annual Report 2022: Time to move to the next stage2023-09-06
-
HA130- Improve the quality of life for dialysis patients2023-09-06
-
Jafron Recognized as National Enterprise Technology Center2023-09-06
-
HA380 hemoperfusion cartridge-- Essential treatments for critical illness2023-09-06
-
Golden Bull Award! Jafron Wins Golden Bull Award for Highest Investment Value o...2023-09-06
-
Expert Consensus on Artificial Liver Therapy2023-09-06
-
Mr. Jean Paul Menneguerre, Senior Head of the EMEA markets of Jafron Biomedical ...2023-09-06
-
Jafron in Jordan: Facilitator of the Local Healthcare Industry2023-09-06
-
ESICM: Getting to Know Jafron from Different Perspectives2023-09-06